title: Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant.
abstract: Mucosal vaccine formulations based on purified recombinant C280 gamma-Intimin and EspB (Escherichia coli secreted protein B) from enterohaemorragic E. coli co-administered with a pegylated derivative of the TLR2/6 agonist MALP-2 (macrophage-activating lipopeptide) as adjuvant were evaluated in BALB/c mice. After intranasal vaccination, strong humoral and cellular immune responses were observed against C280 gamma-Intimin and EspB. Sera of immunized mice inhibit bacterial haemolytic activity in vitro. Antigen-specific T-cell proliferation, IL-4, IL-2 and IFN-gamma producing cells, and secretory IgA were mostly detected in animals receiving MALP-2 as adjuvant. These results suggest that C280 gamma-Intimin and EspB are good candidate antigens to be incorporated into mucosal vaccines against this important pathogen.
authors.affiliation: Institute of Biotechnology, INTA Castelar, Argentina. acataldi@ciudad.com.ar
authors.forename: Angel
authors.initials: A
authors.lastname: Cataldi
authors.forename: Tetyana
authors.initials: T
authors.lastname: Yevsa
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Vilte
authors.forename: Kai
authors.initials: K
authors.lastname: Schulze
authors.forename: Mauricio
authors.initials: M
authors.lastname: Castro-Parodi
authors.forename: Mariano
authors.initials: M
authors.lastname: Larzábal
authors.forename: Cristina
authors.initials: C
authors.lastname: Ibarra
authors.forename: Elsa C
authors.initials: EC
authors.lastname: Mercado
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Guzmán
mesh_terms: D018829:Adhesins, Bacterial / Q000276:immunology*; D000276:Adjuvants, Immunologic; D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D054324:Enterohemorrhagic Escherichia coli / Q000276:immunology*; D004927:Escherichia coli Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D029968:Escherichia coli Proteins / Q000276:immunology*; D022361:Escherichia coli Vaccines / Q000008:administration & dosage* / Q000276:immunology; D005260:Female; D055666:Lipopeptides / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D013601:T-Lymphocytes / Q000276:immunology; D051195:Toll-Like Receptor 2 / Q000819:agonists; D051216:Toll-Like Receptor 6 / Q000819:agonists; D014611:Vaccination
chemical_list: D018829:Adhesins, Bacterial; D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D001425:Bacterial Outer Membrane Proteins; C087863:EaeB protein, E coli; D029968:Escherichia coli Proteins; D022361:Escherichia coli Vaccines; D055666:Lipopeptides; C493486:Tlr2 protein, mouse; C495369:Tlr6 protein, mouse; D051195:Toll-Like Receptor 2; D051216:Toll-Like Receptor 6; C073819:eaeA protein, E coli; C106335:macrophage stimulatory lipopeptide 2